Oncoinvent's Ovarian Cancer Trial with Radspherin® Shows Promising Results After 18 Months

Oncoinvent's Promising 18-Month Data in Ovarian Cancer Treatment

Oncoinvent ASA, a biotech company focused on innovative cancer therapies, has recently published remarkable findings from its Phase 1 clinical trial involving Radspherin®, specifically targeting recurrent ovarian cancer patients. The trial, designated as RAD-18-001, marks a significant stride for Oncoinvent in its mission to address clinical challenges associated with ovarian cancer, particularly regarding peritoneal carcinomatosis, a condition notorious for recurrent tumor growth.

Overview of the Clinical Trial

The Phase 1 trial was initiated to evaluate the safety and efficacy of Radspherin® in patients diagnosed with platinum-sensitive recurrent ovarian cancer. Following the conclusion of patient recruitment in late 2023, the trial is currently focused on long-term follow-up with the initial participants. In total, 10 patients received a single intraperitoneal injection of Radspherin® at a dose of 7 MBq.

Previously, in November 2024, Oncoinvent shared initial 12-month data indicating that merely one participant had experienced a recurrence, marking a mere 10% recurrence rate among the treated group. As of the latest 18-month follow-up, this percentage has notably plateaued, with no additional recurrences reported. This finding is particularly compelling when compared to standard care benchmarks, where approximately 40% of similar patients typically experience recurrence within the same timeframe.

Insights from Clinical Researchers

Dr. Luis Chiva, the Principal Investigator and Director at the Department of Obstetrics and Gynecology at Clinica Universidad de Navarra in Spain, emphasized the significant hurdle posed by ovarian cancer's propensity for recurring even after comprehensive treatment.